Bioinformatics is a technology company.
Bioinformatics has raised $21.0M across 1 funding round.
Bioinformatics has raised $21.0M in total across 1 funding round.
Bioinformatics has raised $21.0M in total across 1 funding round.
Bioinformatics's investors include BroadOak Capital Partners.
Genevia Technologies is a privately held Finnish bioinformatics company founded in 2011, specializing in bioinformatics and data analysis services for omics data in life sciences.[1] It serves academic research groups across Europe and the U.S., as well as major global biotech companies, focusing on biomedical research—especially cancer—alongside molecular biology, microbiology, plants, and animals, by providing expert analysis of complex biological datasets that researchers generate but struggle to process.[1] The company solves the gap between readily available omics experiments and the expertise needed for big data analysis, delivering customizable services with a team of bioinformaticians, data scientists, software developers, and molecular biologists, resulting in robust results, effective communication, and contributions to client publications.[1]
Genevia Technologies was established in 2011 in Tampere, Finland, by a team of experienced bioinformaticians who had collaborated with molecular biology groups.[1] The founders identified a key shift in life sciences toward data-intensive fields, where commercial omics measurements proliferated but analysis lagged, prompting them to assemble top talent in bioinformatics, data science, software development, and molecular biology to set a standard for expert services.[1] Early traction came from addressing this unmet need for frontline researchers and companies, leading to growth into a diverse team offering fully customizable omics analysis for clients in Scandinavia, Western Europe, and North America.[1]
Genevia rides the explosion of omics technologies in life sciences, where high-throughput experiments generate massive datasets but demand specialized computational analysis to unlock insights.[1] Timing aligns with the commercialization of omics measurements since the early 2010s, amplifying needs in precision medicine, cancer research, and biotech amid growing data volumes from NGS and beyond.[1] Market forces like rising biotech R&D, global academic collaborations, and demand for faster drug discovery favor service providers like Genevia, which bridge wet-lab generation and dry-lab interpretation, influencing the ecosystem by enabling more publications, informed decisions, and efficient research without in-house bioinformatics builds.[1]
Genevia is poised to expand its customizable services amid surging omics data in precision oncology and multi-omics integration, potentially deepening ties with biotech for AI-enhanced pipelines. Trends like real-time analysis and federated data sharing will shape its growth, evolving its influence from service provider to key enabler in data-driven life sciences innovation. This positions it strongly in a market where bioinformatics expertise remains a bottleneck for breakthroughs.
Bioinformatics has raised $21.0M across 1 funding round. Most recently, it raised $21.0M Series B in November 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2018 | $21.0M Series B | BroadOak Capital Partners |